This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Edoxaban Treatment Versus Vitamin K Antagonist in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention (ENTRUST-AF-PCI)

This study is currently recruiting participants.
See Contacts and Locations
Verified April 2017 by Daiichi Sankyo, Inc.
European Cardiovascular Research Institute
Kompetenznetz Vorhofflimmern e.V.
Chiltern International Inc.
Information provided by (Responsible Party):
Daiichi Sankyo, Inc. Identifier:
First received: August 10, 2016
Last updated: April 26, 2017
Last verified: April 2017
There are insufficient data on the safety and efficacy of edoxaban plus antiplatelet therapy in subjects with atrial fibrillation AF following percutaneous intervention PCI with stenting. This study is designed to evaluate the safety and to explore the efficacy of an edoxaban-based antithrombotic regimen versus a vitamin K antagonist VKA-based antithrombotic regimen in subjects with AF following PCI with stent placement. Bleeding is a central safety outcome in cardiovascular clinical trials, especially for antithrombotic strategies and invasive procedures.

Condition Intervention Phase
Atrial Fibrillation Drug: Edoxaban Drug: Clopidogrel Drug: Prasugrel Drug: ticagrelor Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Evaluation of the Safety and Efficacy of an Edoxaban-based Compared to a Vitamin K Antagonist-based Antithrombotic Regimen in Subjects With Atrial Fibrillation Following Successful Percutaneous Coronary Intervention (PCI) With Stent Placement.

Resource links provided by NLM:

Further study details as provided by Daiichi Sankyo, Inc.:

Primary Outcome Measures:
  • number of Major or Clinically Relevant non-major ISTH-defined Bleeding (MCRB). [ Time Frame: day 1 to 12 months ]
    number of Major or Clinically Relevant non-major International Society on Thrombosis and Haemostasis ISTH-defined Bleeding (MCRB).

Secondary Outcome Measures:
  • composite number of CV death, stroke, SEE, MI and stent thrombosis events [ Time Frame: day 1 to 12 months ]
    composite of cardiovascular (CV) death, stroke, systemic embolic events (SEE), myocardial infarction (MI) and definite stent thrombosis .</

  • composite number of CV death, stroke, SEE, MI, stent thrombosis events, and ISTH-defined bleeding events [ Time Frame: day 1 to 12 months ]
    Net Clinical Benefit (NCB), defined as the composite of CV death, stroke, SEE, MI, definite stent thrombosis and ISTH-defined major bleeding.

  • number of ISTH-defined major bleeds [ Time Frame: day 1 to 12 months ]
    International Society on Thrombosis and Haemostasis ISTH-defined major bleeding

Estimated Enrollment: 1500
Actual Study Start Date: February 24, 2017
Estimated Study Completion Date: February 2019
Estimated Primary Completion Date: November 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: edoxaban
Edoxaban 60 mg once-daily or 30 mg once-daily in selected subjects
Drug: Edoxaban
Edoxaban 60 mg once-daily or 30 mg once-daily in selected subjects
Other Name: Savaysa
Active Comparator: vitamin k antagonist
Clopidogrel 75 mg once-daily (or in the presence of a documented clinical need prasugrel [5mg or 10 mg once-daily] or ticagrelor [90 mg twice-daily] may be used).
Drug: Clopidogrel
Clopidogrel 75 mg once-daily
Other Name: Plavix
Drug: Prasugrel
prasugrel 5mg or 10 mg once-daily
Other Name: Effient
Drug: ticagrelor
ticagrelor 90 mg twice-daily


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • OAC indication for atrial fibrillation for a period of at least 12 months following successful PCI with stenting.

Eligibility is assessed 4 hours after sheath removal and within 5 days after successful PCI with stent placement. If a staged PCI is planned, eligibility is assessed after completion of the last stage.

Successful PCI definition:

The success of a PCI procedure is defined by 2 interrelated components: angiographic findings, procedural / clinical outcomes as detailed below:

Angiographic Success A minimum stenosis diameter of < 20% (as visually assessed by angiography - residual blockage or stenosis reduced to less than 20% of the artery's diameter).

Sufficient enlargement of the lumen at the target site to improve coronary artery blood flow with final TIMI flow grade 3 (visually assessed by angiography), without occlusion of a significant side branch, flow-limiting dissection, distal embolization, or angiographic thrombus.

Procedural Success No major in-hospital clinical complications(e.g. ongoing ISTH major or clinical relevant non-major procedural bleeding at the time of randomization, stroke, emergency CABG).

In summary, a clinically successful PCI requires both anatomic and procedural success along with relief of signs and/or symptoms of myocardial ischemia at the time of randomization.

Exclusion Criteria:

  • Bleeding risks or systemic conditions
  • Known bleeding diathesis, including but not limited to,

    1. Uncontrolled active bleeding, encompassing both ISTH major and clinically relevant non-major bleeding, preceding randomization.

      Lesion or condition, if considered to be a significant risk for major bleeding. This may include but is not limited to: unresolved gastrointestinal ulceration, presence of malignant neoplasms at high risk of bleeding (e.g. malignancies with metastasis), recent unresolved brain or spinal injury, recent brain, spinal or ophthalmic surgery, any intracranial hemorrhage, known or suspected esophageal varices, arteriovenous malformations, vascular aneurysms (of more than 3.5 cm) or major intraspinal or intracerebral vascular abnormalities.

    2. Medication-related
  • INR > 2.5 (the subject can be reconsidered at a later time, but within 5 days of sheath removal).
  • Contraindication to edoxaban, VKA, ASA and/or P2Y12 antagonists;
  • Concomitant treatment with other antithrombotic agents, fibrinolytic therapy and chronic nonsteroidal anti-inflammatory drugs (NSAIDs).

Concomitant conditions and therapies

  • Critically ill or hemodynamically unstable subjects (at the time of randomization) including:

    1. cardiogenic shock or acute decompensated heart failure, with the requirement for vasopressor agents or inotropic support or mechanical support to support circulation
    2. respiratory failure requiring endotracheal intubation and mechanical ventilation.
  • Any prior mechanical valvular prosthesis;
  • Planned coronary or vascular intervention or major surgery within 12 months; Randomization must be deferred to the last stage in a multistep, multivessel PCI procedure;
  • Moderate or severe mitral stenosis;
  • Ischemic stroke within 2 weeks prior to randomization;
  • Uncontrolled severe hypertension with a systolic blood pressure (BP) ≥180 mmHg and/or diastolic BP ≥ 120 mmHg;
  • Severe renal impairment with estimated creatinine clearance (CrCL) < 15 mL/min or on dialysis;
  • Known abnormal liver function prior to randomization (incl. hepatic disease or biochemical evidence of significant liver derangement known prior to randomization).

Other exclusion criteria

  • Any of the following abnormal local laboratory results prior to randomization:

    1. Platelet count < 50 x109/L
    2. Hemoglobin < 8 mg/dL
  • Unable to provide written IC; Female subjects of childbearing potential without using adequate contraception (female of childbearing potential is defined as one who has not been postmenopausal for at least one year, or has not been surgically sterilised, or has not had a hysterectomy at least three months prior to the start of this study [Visit 1]). Females taking oral contraceptives should have been on therapy for at least three months. Adequate contraceptives include hormonal intra-uterine devices, hormonal contraceptives (oral, depot, patch or injectable), and double barrier methods such as condoms or diaphragms with spermicidal gel or foam.
  • Pregnant or breast-feeding subjects;
  • Assessment that the subject is not likely to comply with the study procedures or have complete follow-up;
  • Participating in another clinical trial that potentially interferes with the current study;
  • Previous randomization in this study;
  • Known drug or alcohol dependence within the past 12 months as judged by the Investigator;
  • Life expectancy < 12 months.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT02866175

Contact: Rahul Malhotra 44(0) 208 9984266
Contact: Dmytro Kobyshcha 38 067 466 9434

  Show 198 Study Locations
Sponsors and Collaborators
Daiichi Sankyo, Inc.
European Cardiovascular Research Institute
Kompetenznetz Vorhofflimmern e.V.
Chiltern International Inc.
Study Chair: Pascal Vranckx, MD Hartcentrum Hasselt
Study Chair: Andreas Gotte, Prof., MD Medizinische Klinik II
  More Information

Responsible Party: Daiichi Sankyo, Inc. Identifier: NCT02866175     History of Changes
Other Study ID Numbers: DSE-EDO-01-15-EU
Study First Received: August 10, 2016
Last Updated: April 26, 2017

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No

Keywords provided by Daiichi Sankyo, Inc.:
percutaneous intervention
vitamin K antagonist

Additional relevant MeSH terms:
Atrial Fibrillation
Arrhythmias, Cardiac
Heart Diseases
Cardiovascular Diseases
Pathologic Processes
Vitamin K
Prasugrel Hydrochloride
Growth Substances
Physiological Effects of Drugs
Platelet Aggregation Inhibitors
Purinergic P2Y Receptor Antagonists
Purinergic P2 Receptor Antagonists
Purinergic Antagonists
Purinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Antifibrinolytic Agents
Fibrin Modulating Agents
Factor Xa Inhibitors
Serine Proteinase Inhibitors
Protease Inhibitors
Enzyme Inhibitors processed this record on September 21, 2017